The Pregnancy and CKD Rare Disease Group have produced a set of recommendations for men taking mycophenolate derivatives and pregnancy following MHRA recommendations.
The RaDaR rare disease registry is now providing us with long term follow-up data for women with kidney disease who have had a pregnancy. This information will help re-define how we can inform, manage and enhance pregnancy outcomes in the future. We will be providing an annual update once sufficient data have been received.
See also Lightstone, L., 2011, Renal Disease and Pregnancy, Medicine, Aug; 39 (8) 497-501.